July 19th 2024
A recent case series reviewed the treatment patterns and effects of therapies on 89 pediatric patients with CCD.
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Studies further condemn UVA reputation
May 1st 2002New Orleans - The role of UVA radiation in generating a number of diseases is now much better understood, Robert Bissonnette, M.D., said at the annual meeting of the American Academy of Dermatology. "If you go back 10 years, we knew a lot about UVB but little about UVA. Now, we know that it can cause skin cancer in animals," he said.
Lesion size, location dictate decision on pediatric surgery
April 1st 2002New Orleans - Timing is key for a successful outcome when performing dermatologic surgery in pediatric patients, and lesion size and location are the two most important variables factoring into the equation, Annette M. Wagner, M.D., said at the annual meeting of the American Academy of Dermatology.
Systemic CD often an elusive diagnosis
April 1st 2002New Orleans - Systemic contact dermatitis may present with a variety of eczematous and noneczematous cutaneous reaction patterns and may be an overlooked diagnosis unless clinicians maintain an index of suspicion that systemic exposure to a contact allergen is driving the skin eruption, Donald V. Belsito, M.D., said at the annual meeting of the American Academy of Dermatology.
Infliximab finds utility in management of pyoderma gangrenosum
April 1st 2002New Orleans - The experiences of an expanding series of patients indicate infliximab (Remicade) is a valuable therapy for the management of pyoderma gangrenosum (PG), Marketa Limova, M.D., said at the annual meeting of the American Academy of Dermatology.